These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25407798)

  • 1. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
    Han CL; Qu CZ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
    Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
    Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
    Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
    Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D
    Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
    Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
    PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
    Younk LM; Uhl L; Davis SN
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
    Henry RR; Buse JB; Wu H; Durrwell L; Mingrino R; Jaekel K; El Azzouzi B; Andjelkovic M; Herz M
    Diabetes Obes Metab; 2015 Jun; 17(6):560-565. PubMed ID: 25728612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
    Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
    Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.